Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2018-A01872-53 | Other Identifier | ID-RCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Assistance Publique - HĆ“pitaux de Paris | OTHER |
| Fondation du Souffle | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The hypothesis of this study is that any of 3 modalities of home non- invasive ventilation (NIV) compared to 'no NIV' (=hospital NIV) will reduce re-admission to hospital or death in COPD patients who remain persistently hypercapnic following an exacerbation requiring NIV.
By 2020, chronic obstructive pulmonary disease (COPD) is expected to be the 3rd leading cause of death in the world, especially in countries of middle to high income, like EU. Despite the improvements in survival by using acute non- invasive ventilation (NIV) to treat patients with exacerbations of COPD complicated by acute hypercapnic respiratory failure (AHRF), these patients are at high risk of re-admission and further life-threatening events. Furthermore, in a recent study of 110 patients who had AHRF (RESCUE study, Struik, Thorax 2014), at one year after discharge 65% had another life-threatening event, and 49% had died. New recent data suggests that NIV at home can reduce re-admissions (HMV-LTOT, Murphy, JAMA 2017), but in a small proportion of patients, and with a high level of expertise. There is an urgent need to develop strategies to reduce the number and severity of exacerbations of COPD. With healthcare objectives and budget constraints, telemonitoring of COPD patients is an important challenge in most European countries. RESCUE2-Monitor is the next step. This European trial (currently, France, Spain and Portugal) will test the hypothesis that home NIV, with a highly adapted ventilatory strategy (hereafter referred to as 'TARGETED VENTILATION'), compared to no home NIV (only hospital NIV), to non-targeted home NIV or to rescue home NIV will reduce re-admission to hospital or death in COPD patients, is possible using e-medicine, and will reduce costs of health.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control group | No Intervention | no home non-invasive ventilation (NIV), only hospital NIV | |
| Non-targeted home NIV | Active Comparator | Nocturnal home non-invasive ventilation (NIV) |
|
| Targeted home NIV | Active Comparator | Nocturnal home non-invasive ventilation (NIV) with high monitoring |
|
| Rescue home NIV | Active Comparator | home non-invasive ventilation (NIV) on demand |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| home ventilators | Device | The 3 test treatments are home non-targeted NIV, home targeted NIV and rescue home NIV. COPD patients will be equipped with home ventilators and fitted with either nasal, oronasal or facial masks. All the ventilators used will be CE marked. |
| Measure | Description | Time Frame |
|---|---|---|
| admission-free survival | defined as time from randomisation to hospital admission in relation with severe exacerbation of COPD or death from any cause, whichever event occurred first, estimated using the Kaplan-Meier method. If neither event occurs, then time will be taken from day randomisation to the last known follow up visit. If withdrawal occurs prior to death, time will be taken from the day of randomisation to day of withdrawal. | 0-36 months |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival | estimated using the Kaplan-Meier method | 0-36 months |
| Frequency of exacerbations requiring hospitalization | The number of patients that experience one or more exacerbations resulting in hospitalisation |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| AngĆØle Guilbot | Contact | +33-180-13-15-19 | angele.guilbot@multihealthgroup.com | |
| Nathalie Gagne | Contact | +33-180-13-14-70 | nathalie.gagne@clinact.com |
| Name | Affiliation | Role |
|---|---|---|
| Jesus Gonzalez, MD | HĆ“pital PitiĆ© SalpĆŖtriĆØre-Charles Foix, Paris, France , | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Groupe Hospitalier PitiĆ© SalpĆŖtriĆØre-Charles Foix | Recruiting | Paris | Ćle-de-France Region | 75651 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33092618 | Derived | Rescue2-monitor group. Respiratory support in COPD patients after acute exacerbation with monitoring the quality of support (Rescue2-monitor): an open-label, prospective randomized, controlled, superiority clinical trial comparing hospital- versus home-based acute non-invasive ventilation for patients with hypercapnic chronic obstructive pulmonary disease. Trials. 2020 Oct 22;21(1):877. doi: 10.1186/s13063-020-04672-w. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
Rescue2-monitor is an open-label, prospective randomized, controlled, superiority clinical trial, performed in patients with hypercapnic chronic obstructive pulmonary disease post-acute hypercapnic exacerbation. Four arms (distributed between groups at a ratio of 1:1:1:1) will be compared: no home NIV 'hospital NIV' (control group) versus any of 3 modalities of home NIV (experimental groups). The 3 experimental treatments are Nocturnal home NIV 'non-targeted home NIV', Nocturnal home NIV with high monitoring 'targeted home NIV', and 'rescue home NIV'.
Not provided
Not provided
Not provided
Not provided
| 12 months |
| Frequency of exacerbations resulting in physician directed treatment | The number of patients that experience an exacerbation resulting in physician directed treatment, self-management or no treatment change; | 12 months |
| Assessment of Exacerbation based on changes in arterial pressure of carbon dioxide | Change in arterial partial pressure of carbon dioxide (PaCO2) in mmHg | 0, 1, 3, 6, 12, 18, 24, 30 and 36 months |
| Assessment of Exacerbation based on changes in arterial partial pressure of oxygen | Change in arterial partial pressure of oxygen (PaO2) severe respiratory insufficiency in mmHg | 0, 1, 3, 6, 12, 18, 24, 30 and 36 months |
| Assessment of Quality of life with St George's respiratory questionnaire | Evolution of scores obtained at the St George's respiratory questionnaire. Scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. | 0,1, 3, 6, 24 and 36 months |
| Assessment of Quality of life with Severe Respiratory Insufficiency Questionnaire | Evolution of scores obtained at the Severe Respiratory Insufficiency Questionnaire The SRI consists of seven subscales covering 49 items: Respiratory Complaints (SRI-RC), Physical Functioning (SRI-PF), Attendant Symptoms and Sleep (SRI-AS), Social Relationships (SRI-SR), Anxiety (SRI-AX), Psychological Well-Being (SRI-WB), and Social Functioning (SRI-SF). These seven subscales can be summarised to one Summary Scale (SRI-SS). All items relate to the patients' circumstances of the last week. Rating for each item is provided by a five-point Likert-scale, a scaling method which measures either positive or negative responses to a given statement with five possible grading steps ranging from "strongly agree" to "strongly disagree". Higher scores are attributed to better Health Related Quality of life. | 0,1, 3, 6, 24 and 36 months |
| Assessment of Quality of life with SF-36 | Evolution of scores obtained at SF-36 questionnaire. The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. | 0,1, 3, 6, 24 and 36 months |
| Assessment of Quality of life with the 5-level EQ-5D version | Evolution of scores obtained at the EQ5D5L, a standardised measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal1 | 0,1, 3, 6, 24 and 36 months |
| Assessment of Quality of life with the Charlson Comorbidity Index | Evolution of the Charlson Comorbidity Index, a method of categorizing comorbidities of patients based on the International Classification of Diseases (ICD). A score of zero indicates that no comorbidities were found. The higher the score, the more likely the predicted outcome will result in mortality or higher resource use. | 0,1, 3, 6, 24 and 36 months |
| Assessment of Quality of life with the COPD Assessment Test (CAT) | Evolution of the CAT score. The COPD Assessment Test (CAT) is a questionnaire for people with COPD. It is designed to measure the impact of COPD on a person's life, and how this changes over time. | 0,1, 3, 6, 24 and 36 months |
| Assessment of Quality of sleep with Pittsburgh Sleep Quality Index | Evolution of the Pittsburgh Sleep Quality Index. The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1-month time interval. The measure consists of 19 individual items, creating 7 components that produce one global score. Each item is weighted on a 0-3 interval scale. The global PSQI score is then calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where lower scores denote a healthier sleep quality. | 0,1, 3, 6, 24 and 36 months |
| Assessment of Quality of sleep with Epworth Sleepiness Scale | Evolution of the score of Epworth Sleepiness Scale. The questionnaire asks the subject to rate his or her probability of falling asleep on a scale of increasing probability from 0 to 3 for eight different situations that most people engage in during their daily lives, though not necessarily every day. The scores for the eight questions are added together to obtain a single number. A number in the 0-9 range is considered to be normal while a number in the 10-24 range indicates that expert medical advice should be sought | 0,1, 3, 6, 24 and 36 months |
| Assessment of dyspnea with Modified Medical Research Council (mMRC) scale | Evolution of the mMRC score. Dyspnea in daily living was evaluated by the mMRC scale which consists in five statements that describe almost the entire range of dyspnea from none (Grade 0) to almost complete incapacity (Grade 4) | 0,1, 3, 6, 24 and 36 months |
| Adverse events (AEs) frequency | Serious adverse events (SAEs) occurrence rate. | 0, 3, 6, 12, 18, 24 and 36 months |
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |